The Conversation (0)
La Jolla Pharmaceutical Announces Launch of GIAPREZA™ (angiotensin II) in the United States
Mar. 23, 2018 08:51AM PST
Biotech Investing
La Jolla Pharmaceutical (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved by the U.S. Food and Drug Administration (FDA) to increase blood pressure in adults with septic or other distributive shock. As quoted in the press release: GIAPREZA mimics the body’s endogenous regulatory peptide that is …
La Jolla Pharmaceutical (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved by the U.S. Food and Drug Administration (FDA) to increase blood pressure in adults with septic or other distributive shock.
As quoted in the press release:
GIAPREZA mimics the body’s endogenous regulatory peptide that is central to the renin-angiotensin-aldosterone system to increase blood pressure. GIAPREZA is available in 1 mL single-dose vials, each containing 2.5 mg of angiotensin II (as a sterile liquid).